Zota Health Care LImited has informed the Exchange about Transcript
ZOTA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zota Health Care reported consolidated revenue of INR 103.58 crores in Q1FY26, up 84% year-on-year, driven mainly by DavaIndia which contributed 73% of revenue (INR 75.62 crores, 111% growth). EBITDA turned positive at INR 4.83 crores with a margin of 4.7%, improving from 3.6% in Q4FY25, supported by maturing COCO stores. The DavaIndia generic pharmacy chain expanded to 1,745 stores (986 COCO, 759 FOFO), with 163 new stores added in the quarter. GMV grew 88% YoY to INR 87.78 crores and footfalls more than doubled. Management confirmed plans to open around 800 COCO and 150-200 FOFO stores in FY26, flagged a possible 5,000-store target in 2-3 years, and indicated meaningful profitability shift once 600-700 stores reach the 18-36 month mature bracket (12-18 months away). Suniel Shetty was appointed brand ambassador, the B2C app is now live PAN India, and marketing spend (currently under 5% of revenue) will moderately rise.
Strong topline growth and a clear margin improvement trajectory are positive signals, but consolidated EBITDA margin remains thin at 4.7% and PAT-level breakeven is still 12-18 months away as most stores are immature. Aggressive store expansion and rising marketing spend could pressure near-term margins, though long-term store economics (30% EBITDA in 36+ month stores) are encouraging.